Aurinia restructures board, bringing in Kevin Tang and keeping CEO

Max Bayer

Pharma Reporter

Aurinia Pharmaceuticals offered an olive branch to a group of shareholders clamoring for change. It’s shrinking its board by two seats, and it added activist …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aurinia restructures board, bringing in Kevin Tang and keeping CEO

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

All of 23andMe's independent board members resign over disagreements with CEO

Bad trip: How culture conflict and a need for cash nearly broke Lykos

Novartis’ Kisqali snags FDA approval to reduce recurrence in patients with early forms of breast cancer

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3

Breaking down silos with a new quantitative approach to drug development

Au­rinia re­struc­tures board, bring­ing in Kevin Tang and keep­ing CEO

Pharma Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Aurinia restructures board, bringing in Kevin Tang and keeping CEO